APA (7th ed.) Citation

Mori, K., Emoto, M., Numaguchi, R., Yamazaki, Y., Urata, H., Motoyama, K., . . . Inaba, M. (2017). POTENTIAL ADVANTAGE OF REPAGLINIDE MONOTHERAPY IN GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND SEVERE RENAL IMPAIRMENT. Acta Endocrinologica (1841-0987), 13(2), 133. https://doi.org/10.4183/aeb.2017.133

Chicago Style (17th ed.) Citation

Mori, K., M. Emoto, R. Numaguchi, Y. Yamazaki, H. Urata, K. Motoyama, T. Morioka, T. Shoji, and M. Inaba. "POTENTIAL ADVANTAGE OF REPAGLINIDE MONOTHERAPY IN GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND SEVERE RENAL IMPAIRMENT." Acta Endocrinologica (1841-0987) 13, no. 2 (2017): 133. https://doi.org/10.4183/aeb.2017.133.

MLA (9th ed.) Citation

Mori, K., et al. "POTENTIAL ADVANTAGE OF REPAGLINIDE MONOTHERAPY IN GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND SEVERE RENAL IMPAIRMENT." Acta Endocrinologica (1841-0987), vol. 13, no. 2, 2017, p. 133, https://doi.org/10.4183/aeb.2017.133.